Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 00:05 | 2026-03-02 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | SALE | $35.30 | 10,305 | $363,767 | 16,080 | -39.1% |
| 2026-01-10 00:05 | 2026-01-07 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.48 | 10,000 | $404,800 | 16,080 | -38.3% |
| 2025-11-14 00:05 | 2025-11-11 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.41 | 2,642 | $106,763 | 15,932 | -14.2% |
| 2025-11-11 00:05 | 2025-11-06 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $40.47 | 7,358 | $297,778 | 15,932 | -31.6% |
| 2025-03-06 00:05 | 2025-03-03 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $49.52 | 10,000 | $495,200 | 15,539 | -39.2% |
| 2024-03-13 23:05 | 2024-03-11 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | SALE | $44.71 | 7,874 | $352,047 | 949 | -89.2% |
| 2023-12-02 00:05 | 2023-11-30 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $35.41 | 17,447 | $617,798 | 827 | -95.5% |
| 2021-10-28 23:09 | 2021-10-26 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $50.57 | 10,000 | $505,689 | 5,696 | -63.7% |
| 2021-08-18 23:05 | 2021-08-16 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $48.03 | 15,000 | $720,480 | 5,623 | -72.7% |
| 2021-07-14 23:13 | 2021-07-12 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $53.54 | 20,000 | $1,070,876 | 5,623 | -78.1% |
| 2020-12-24 00:10 | 2020-12-21 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $26.28 | 30,000 | $788,400 | 2,279 | -92.9% |
| 2020-06-24 23:19 | 2020-06-23 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $15.01 | 14,751 | $221,413 | 1,622 | -90.1% |
| 2020-06-18 23:03 | 2020-06-16 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $15.00 | 4,002 | $60,030 | 1,622 | -71.2% |
| 2019-11-13 00:03 | 2019-11-11 | VCEL | Vericel Corp | Halpin Michael | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $18.53 | 15,047 | $278,821 | 1,034 | -93.6% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.